Welcome to our dedicated page for Sarepta Therapeutics SEC filings (Ticker: SRPT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Sarepta Therapeutics, Inc. (SRPT) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. Sarepta is a biotechnology issuer listed on the NASDAQ Global Select Market, and its filings offer detailed insight into its precision genetic medicine business, capital structure and risk profile.
For investors analyzing SRPT, Forms 10-K and 10-Q (when available) describe Sarepta’s focus on rare diseases, including Duchenne muscular dystrophy, and its portfolio of RNA-targeted and gene transfer therapies. These periodic reports typically discuss marketed products such as ELEVIDYS and PMO exon-skipping therapies, outline research and development priorities across muscle, central nervous system and cardiac diseases, and present management’s view of key risks and uncertainties.
Current reports on Form 8-K are particularly relevant for Sarepta, as they document material events such as exchange transactions involving its 1.25% Convertible Senior Notes due 2027 and new 4.875% Convertible Senior Notes due 2030, private placements of common stock, strategic restructuring actions and executive transitions. These filings also reference press releases that announce quarterly financial results, clinical trial milestones, FDA decisions on ELEVIDYS labeling, and clinical holds affecting certain limb girdle muscular dystrophy gene therapy programs.
Users interested in capital markets activity and potential dilution can review disclosures about unregistered sales of equity securities, convertible note terms, and related exchange agreements. Over time, proxy statements and other governance-related filings can provide additional detail on board structure and compensation policies.
Stock Titan enhances these SRPT filings with AI-powered summaries that explain complex sections in plain language, highlight key changes from prior periods and surface items such as revenue drivers, pipeline updates and financing terms. Real-time updates from EDGAR, along with structured access to Form 4 insider transaction reports when filed, help investors monitor how Sarepta’s regulatory disclosures evolve as its genetic medicine programs progress.
Sarepta Therapeutics director Claude Nicaise exercised stock options and adjusted his shareholdings. On January 29, 2026, he exercised 10,500 stock options at $13.71 per share, receiving 10,500 shares of common stock.
On the same date, 6,780 common shares were withheld by Sarepta, noted as satisfying payment of the option exercise price. After these transactions, Nicaise directly owned 31,532 shares of Sarepta common stock.
Sarepta Therapeutics director M. Kathleen Behrens reported an option exercise and related share withholding. On January 27, 2026, she exercised a stock option for 10,500 shares of common stock at $13.71 per share, converting a derivative award into owned stock.
To cover the option exercise cost, 6,494 shares of common stock were withheld by Sarepta at a price of $22.17 per share, as explained in the footnote. After these transactions, she held 197,482 shares of common stock directly and 10,000 shares indirectly through a trust.
BlackRock, Inc. filed an amended ownership report showing it beneficially owns 13,232,652 shares of Sarepta Therapeutics common stock, representing 12.6% of the class as of 12/31/2025. BlackRock reports sole voting power over 12,913,969 shares and sole dispositive power over the full 13,232,652 shares, with no shared voting or dispositive authority.
The filing aggregates holdings of certain BlackRock business units and notes that one holder, iShares Core S&P Small-Cap ETF, has an interest exceeding five percent of Sarepta’s outstanding common stock. BlackRock certifies that the shares were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of Sarepta, other than permitted nomination-related activities.
Sarepta Therapeutics, Inc. furnished a current report to share that it issued a press release with certain business updates and preliminary financial information for the year and fiscal quarter ended December 31, 2025. The disclosure was made in connection with the 44th Annual J.P. Morgan Healthcare Conference, highlighting recent operational and financial developments.
The press release is included as Exhibit 99.1 to the report and is incorporated by reference. The company specifies that this information is being furnished under Item 2.02, rather than filed, which limits how it is treated under securities law unless another filing specifically incorporates it by reference.
Sarepta Therapeutics plans a private exchange of approximately $291.4 million of its 1.25% Convertible Senior Notes due 2027 for the same principal amount of new 4.875% Convertible Senior Notes due 2030 plus about $31.6 million in cash.
The new notes will be issued as additional notes under Sarepta’s existing 4.875% 2030 convertible notes indenture, bringing the total principal of that series to $893.4 million after closing, which is expected on or about December 18, 2025, subject to customary conditions. The exchange, which includes participation by a trust affiliated with director Michael Chambers, is limited to institutional accredited investors and qualified institutional buyers under a private placement exemption, and the new notes and underlying shares will not be registered for public resale.
Sarepta Therapeutics, Inc. (SRPT) reported an insider equity transaction by its President, R&D and Tech Ops, filed on a Form 4. On 11/17/2025, the officer had 4,582 shares of common stock withheld by the company at a price of $18.42 per share to cover tax obligations arising from the vesting of previously granted restricted stock units. Following this tax-withholding transaction, the officer directly beneficially owned 224,030 shares of Sarepta common stock.
Sarepta Therapeutics (SRPT) reported Q3 2025 results. Total revenues were $399.4 million versus $467.2 million a year ago, with product revenues of $370.0 million and collaboration and other revenues of $29.3 million. ELEVIDYS U.S. product revenue was $131.5 million versus $181.0 million, and PMO product revenues were $238.5 million versus $248.8 million.
The company posted an operating loss of $103.4 million and a net loss of $179.9 million for the quarter. Year to date, total revenues reached $1.76 billion versus $1.24 billion, but the company recorded a net loss of $430.6 million driven by a $583.6 million acquired IPR&D expense from the Arrowhead deal and a $138.6 million loss on debt extinguishment tied to a 2027-to-2030 notes exchange.
Cash and cash equivalents were $613.1 million, with short‑term investments of $237.9 million. Deferred revenue current portion rose to $485.4 million. The company repurchased $25.3 million of stock under a $500 million authorization. Sarepta suspended commercial shipments of ELEVIDYS to non‑ambulatory patients in June 2025 and is in ongoing FDA discussions regarding a labeling supplement, including a boxed warning for acute liver injury and acute liver failure and removal of the non‑ambulatory population from Indication and Usage.
Sarepta Therapeutics (SRPT) reported that it issued a press release announcing its financial results for the quarter ended September 30, 2025. The company furnished the full text of the release as Exhibit 99.1 to this Form 8-K.
The company stated that the information in Item 2.02, including Exhibit 99.1, is furnished and not deemed filed for purposes of Section 18 of the Exchange Act, and is not incorporated by reference into other filings except as expressly set forth by specific reference.
The Vanguard Group filed Amendment No. 11 to Schedule 13G for Sarepta Therapeutics, Inc. (SRPT), reporting ownership of 10,641,733 shares, equal to 10.89% of the outstanding common stock. Vanguard reports 0 sole voting power, 606,072 shared voting power, 9,925,846 sole dispositive power, and 715,887 shared dispositive power. The filing states these shares are held in the ordinary course of business and are not intended to influence control of the issuer. The filing identifies Vanguard's Malvern, PA address and is signed by Ashley Grim, Head of Global Fund Administration, dated 09/08/2025.
Louise Rodino-Klapac, President of R&D and Tech Ops at Sarepta Therapeutics (SRPT), reported insider acquisitions on Form 4. On 09/03/2025 she was granted two awards of restricted stock units (RSUs): 93,875 RSUs that vest 50% on 09/03/2026 and 50% on 09/03/2027, and 50,000 performance-based RSUs that vest 100% on 09/03/2028 subject to service and achievement of performance criteria. The transactions were reported as acquisitions at $0 per share because they are equity awards. Following the grants and an earlier purchase of 106 shares on 08/31/2025 under the ESPP, she beneficially owned 228,612 shares after the reported transactions.
FAQ
What is the current stock price of Sarepta Therapeutics (SRPT)?
What is the market cap of Sarepta Therapeutics (SRPT)?
